Emavusertib (CA-4948) in combination with ibrutinib in patients with relapsed/refractory primary central nervous system lymphoma (R/R PCNSL) Meeting Abstract
| Authors: | Grommes, C.; Tun, H. W.; de la Fuente Burguera, A. D.; Dabrowska-Iwanicka, A.; Regales, L.; Zhao, W.; Ferrari, D.; Fowles, M.; Lane, M. E.; Wang, C.; Von Roemeling, R. W.; Taszner, M.; D'angelo, C.; Nowakowski, G. S. |
| Abstract Title: | Emavusertib (CA-4948) in combination with ibrutinib in patients with relapsed/refractory primary central nervous system lymphoma (R/R PCNSL) |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557400445 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.2087 |
| Notes: | Meeting Abstract: 2087 -- Source: Wos |
